{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG000","lowerLimit":"20.0","upperLimit":"NA","value":"290.5"},{"groupId":"OG001","lowerLimit":"75.0","upperLimit":"404.0","value":"179.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG002","lowerLimit":"344.0","upperLimit":"NA","value":"491.0"},{"groupId":"OG003","lowerLimit":"92.0","upperLimit":"733.0","value":"492.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG004","lowerLimit":"52.0","upperLimit":"NA","value":"485.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG005","lowerLimit":"20.0","upperLimit":"NA","value":"264.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"Overall survival was defined as the interval between the Baseline visit (Day 1) and the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with programmed cell death protein/programmed cell death ligand 1 (PD-1/PD-L1) relapsed melanoma (RM) received INCAGN01876 300 mg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.","id":"OG000","title":"Phase 2 Group C2 PD-1/PD-L1 RM: INCAGN01876 300 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with gastric cancer (GC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG001","title":"Phase 2 Group F GC: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with squamous cell carcinoma of the head and neck (SCCHN) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG002","title":"Phase 2 Group F SCCHN INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with cervical cancer (CC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG003","title":"Phase 2 Group F CC: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with PD-1/PD-L1 relapsed melanoma received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG004","title":"Phase 2 Group F PD-1/PD-L1 RM: INCAGN01876 300 mg + Nivolumab 240 mg"},{"description":"Participants with gastric cancer, squamous cell carcinoma of the head and neck, cervical cancer, or PD-1/PD-L1 relapsed melanoma who had tumor lesions that were amenable to percutaneous biopsy received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG005","title":"Phase 2 Group F Biopsy: INCAGN01876 300 mg + Nivolumab 240 mg"}],"paramType":"MEDIAN","populationDescription":"Phase 2 FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","timeFrame":"up to approximately 44.7 months","title":"Phase 2: Overall Survival","type":"SECONDARY","unitOfMeasure":"Days"}